Carolina Rudah
Sen. Elizabeth Warren (D-MA) is calling on the Federal Trade Commission to carefully evaluate Novo Nordisk Foundation's planned $16.5 billion acquisition of Catalent (NYSE:CTLT).
"I am concerned that this deal could increase Novo Nordisk’s dominance2 over vital GLP-1 inhibitor drugs, reducing